layer brist-en stori
bloomberg report potenti starboard stake bloomberg
report weekend activist hedg fund starboard taken
invest stake report confirm
starboard bristol size stake plan starboard may
also known report
involv could open addit possibl
bmy/celg sinc bristol announc plan acquir celgen
mani investor ask us deal might potenti get disrupt
believ anoth biopharma compani step make hostil
bid buy bristol unlik howev possibl activist come
push bristol look option includ mayb look
potenti buyer also rais interest would note
activist involv bristol past coupl year
may led chang board manag team
obvious sale compani overlap top
holder celg per sept data factset
could influenc discuss potenti activist may proceed
addit thought propos bmy/celg deal pleas
see note recent publish
dive deeper brist-en forma model potenti deal
answer addit burn question bmy/celg
new year firework propos acquisit celg
note follow-up call bristol ir earn
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
figur larg cap biopharma compani could potenti view bristol takeout target
bn usd
potenti interest
n/a applic boehring ingelheim privat compani report valu
alreadi xarelto would make deal complic
size oncolog presenc make sens
size would get full eliqui right would need
divest bavencio importantli new ceo suggest larg
transform deal current attract
alreadi tecentriq deal would make sens
product mix mesh well size cash flow could support
attract bid manag guid toward platform
alreadi keytruda deal would make sens
product mix mesh well size cash flow could support
attract bid although may interest eliqui
product mix mesh well size cash flow could support
could make sens paper never done deal remot
close size acquir loxo
primarili diabet focus would make sens strateg
portfolio overlap lovenox libtayo like enough
room balanc sheet attract offer
would make sens oncolog presenc unlik due
on-going tesaro acquisit balanc sheet requir
like enough room balanc sheet attract offer
alreadi imfinzi current focu commerci
like enough room balanc sheet attract offer
alreadi xarelto would make sens follow monsanto
product portfolio dissimilar
product portfolio dissimilar
alreadi bavencio big enough make offer
alreadi libtayo big enough make offer
difficult evalu privat compani think unlik
rule possibl
compani mention price
